N/A
N=421
Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections
Upper Respiratory Tract Infections
Bottom Line
View on ClinicalTrials.gov: NCT00827502 ↗Enrolled (actual)
421
Serious AEs
0.0%
Results posted
Jun 2010
Primary outcome: Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Jul 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study |
275; 133 | — |
| PRIMARY Number of Subjects With an Investigator Assessment of Clinical Outcome (Cure/Improvement/Failure) at End of Study |
249; 26; 3 | — |
| SECONDARY Cost (in Indian Rupees) Per Participant of Utilizations Including General Consultations, Medications, Chest X-ray, Complete Blood Count, and Erythrocyte Sedimentation Rate |
500; 170; 18; 9; 20; 20 | — |
Summary
To assess effectiveness of Trulimax (Azithromycin) in Acute Bacterial Upper Respiratory Tract Infections (URTIs).
Eligibility Criteria
Inclusion Criteria
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- Patients with acute URTI, presumed to be of bacterial origin as per the clinical judgment of the investigator.
Exclusion Criteria
N/A
Data sourced from ClinicalTrials.gov (NCT00827502). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.